Sector Update: Health Care Stocks Mixed Premarket Friday
9:14AM ET 7/01/2022 MT NewswiresHealth care stocks were mixed premarket Friday. The Health Care SPDR (XLV) was 0.28% lower, and the iShares NASDAQ Biotechnology Index (IBB) was recently...
Quotes Snapshot > CYTK
Cytokinetics Inc CYTK:NASDAQ
Last Price$41.00NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22
Today's Change+1.71(4.35%)
Bid (Size)$40.92 (1)
Ask (Size)$42.90 (3)
Day Low / High$38.54 - 42.50
Volume7.4 M
Read more news Recent News
Cytokinetics Prices $450 Million Private Placement of Convertible Notes; Doubles Development Loan
4:00AM ET 7/01/2022 MT NewswiresCytokinetics (CYTK) said Friday it has priced a private placement of $450 million principal amount of 3.5% convertible senior notes due 2027. Initial...
Sector Update: Health Care Stocks Swoon Late, Closing Lower
4:06PM ET 6/30/2022 MT NewswiresHealth care stocks slipped fully below the surface this afternoon, with the NYSE Health Care Index falling 0.2% and the SPDR Health Care Select Sector ETF...
Sector Update: Health Care Stocks Little Changed on Thursday
1:59PM ET 6/30/2022 MT NewswiresHealth care stocks were narrowly mixed this afternoon, with the NYSE Health Care Index sliding 0.1% while the SPDR Health Care Select Sector ETF (XLV) was...
View all Commentary and Analysis
Cytokinetics: Emerging Leader In Heart Failure Drugs, But Let It Truly Emerge First
8:01AM ET 6/27/2022 Seeking AlphaCytokinetics, Incorporated (CYTK) CEO Robert Blum on Q1 2022 Results - Earnings Call Transcript
10:15PM ET 5/04/2022 Seeking AlphaCytokinetics: A Brighter Future In Muscle Biology
3:59PM ET 4/11/2022 Seeking AlphaCytokinetics (CYTK) Investor Presentation - Slideshow
1:21PM ET 3/16/2022 Seeking AlphaCompany Profile
Business DescriptionCytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA. View company web site for more details
| Address | 350 Oyster Point Boulevard South San Francisco, California 94080 |
| Phone | +1.650.624.3000 |
| Number of Employees | 130 |
| Recent SEC Filing | 06/24/2022 8-K |
| President, Chief Executive Officer & Director | Robert I. Blum |
| Vice President-Development Operations | Eric Terhaerdt |
| Chief Financial Officer & Senior Vice President | Ching W. Jaw |
| Executive Vice President-Research & Development | Fady Ibraham Malik |
Company Highlights
| Price Open | $42.50 |
| Previous Close | $39.29 |
| 52 Week Range | $17.72 - 49.41 |
| Market Capitalization | $3.5 B |
| Shares Outstanding | 85.7 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/04/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$3.20 |
| Beta vs. S&P 500 | N/A |
| Revenue | $31.5 M |
| Net Profit Margin | -396.22% |
| Return on Equity | -164.73% |
Analyst Ratings as of 01/31/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |